Stories
Domestic Pharma Market Hits Six-Quarter High in Q2FY27 on Volume Recovery
- •The Indian pharmaceutical market grew 12 percent by value in Q2FY27, driven by prescription demand recovery, pricing, and chronic therapies.
- •Unit growth accelerated to 2.3 percent, while price growth contributed 6.1 percentage points and new product launches added 3.6 percentage points.
- •Cardiac therapies led the market with a 14.1 percent share and 15.3 percent value growth, supported by anti-diabetic and specialty segments.
- •GLP-1 therapies surged 72 percent, with Eli Lilly's Mounjaro becoming India's largest pharmaceutical brand with Rs 1,504 crore in annualised sales.
Key Questions Answered
The Indian pharmaceutical market grew 12 percent by value in Q2FY27, hitting a six-quarter high driven by a broad-based recovery in prescription demand, higher pricing, and the continued expansion of chronic therapies. Unit growth accelerated to 2.3 percent, while price growth contributed 6.1 percentage points and new product launches added 3.6 percentage points.
Cardiac therapies remained the largest contributor with a 14.1 percent share and 15.3 percent value growth, while vaccines were the fastest-growing area, expanding 21.2 percent. Anti-diabetic therapies rose 16.5 percent, powered significantly by GLP-1 therapies which surged 72 percent. Eli Lilly's Mounjaro became India's largest pharma brand with Rs 1,504 crore in annualised sales.
GLP-1 therapies accounted for 13 percent of the diabetes market and delivered a striking 72 percent growth, driven by an 81 percent contribution from new products despite a volume decline. Overall, new product launches added 3.6 percentage points to the broader pharmaceutical market's growth during the quarter.
